

Review Article

Dynamicity of Immune Regulation during Visceral Leishmaniasis

M D ASAD and NAHID ALI*

Infectious Diseases and Immunology Division, Indian Institute of Chemical Biology, 4, Raja SC Mullick Road, Jadavpur, Kolkata 700 032, West Bengal, India

(Received on 22 July 2013; Revised on 16 December 2013; Accepted on 24 March 2014)

Visceral leishmaniasis is a vector-borne tropical disease associated with a spectrum of clinical manifestations and immunosuppression leading to parasite survival. Chemokines which act as chemo-attractants for generating innate immune responses are significant in bringing innate and adaptive responses side by side for combating against infection. The independency and interdependency of regulatory T cells and Th17 cells on Th1/Th2 signalling pathways and an imbalance in immune responses could lead to disease progression. Although Interleukin- (IL-)12 is crucial in generating protective Th1 response against the disease, various members of the IL-12 family perform diverse immune functions due to their chain pairing promiscuity. This review focuses on the immunopathogenesis of VL by chronologically summarising the developments in the studies of the immune regulation as well as the mechanisms involved. A better understanding of the innate and adaptive immune functioning of the host could aid in rational control and better therapeutic intervention of the disease.

Key Words: Immunology; Leishmaniasis; Cytokine; Chemokine; Regulatory Cell; Immune Cell; Innate Immunity; Adaptive Immunity; Memory Response

Introduction

Visceral leishmaniasis (VL), also known as kala-azar, is caused by the protozoan parasites of the genus *Leishmania* that includes *Leishmania donovani*, *Leishmania chagasi* and *Leishmania infantum*. VL is prevalent in more than eighty countries (Choi and Lerner, 2001) worldwide. Of them approximately 90% of VL cases are reported in Bangladesh, India, Ethiopia, Sudan, South Sudan, and Brazil (Alvar *et al.*, 2012). The characteristic symptoms of VL include irregular bouts of fever, substantial weight loss, swelling of the spleen and liver, and anaemia. The disease is fatal if left untreated. VL is an immunosuppressive disease with most of the patients showing negative leishmanin skin test (Gidwani *et al.*, 2009). It could be an interesting topic to explore since the proliferative response of peripheral blood mononuclear cells (PBMC) from such active VL patients is poor.

In VL, the beginning of infection is marked by recruitment of innate immune cells such as, neutrophils, macrophages, natural killer (NK) cells and dendritic cells (DCs) at the site of infection due to the secretion of different chemoattractant proteins. Later these recruitments generate a mixed regulatory and inflammatory responses by secreting chemokines and cytokines. These responses are exhibited generally by low levels of IL-12 or IFN- γ and elevated production of IL-10, TGF- β , IL-4 and IL-13 in leishmanial antigens stimulated culture supernatants of VL patients. Contradictory reports are also there manifesting increased level of IFN- γ mRNA in both liver and spleen of the infected subjects (Saha *et al.* 2007; Nysten *et al.* 2007; Sacks *et al.*, 1987). Similar observations were made in murine VL, where both IL-10 and TNF- α production were found to be elevated in the spleen. TNF- α , which is critical for the development of protective immunity, causes

*Author for Correspondence: E-mail: nali@iicb.res.in; Phone: 91-33-2499-5757

granuloma formation in the liver, but may also induce IL-10 secretion to control the tissue damage (Ato *et al.*, 2002). Enhanced IL-10, besides inhibiting macrophage activation and granuloma formation, also promotes parasite persistence through its immunosuppressive mechanisms (Ato *et al.*, 2002; Murray *et al.*, 2000; Stanley *et al.*, 2007; Buxbaum 2013; Murray *et al.*, 2002).

IL-27, a cytokine central in regulation of Th17 cells, is mainly produced by antigen presenting cells. Studies in mice have demonstrated that this cytokine can inhibit the differentiation of Th17 cells. IL-27 could also act synergistically with IL-10 and TGF- β in inducing disease pathogenicity (Chen and Liu 2009; Belkaid *et al.*, 2001). TGF- β , on the other hand, is essential for the induction of FoxP3⁺ Regulatory T (Treg) cells. Additionally it could also inhibit the generation of Th1 cells, leading to disease progression (Batten *et al.*, 2006). Treg cells are considered as masters of immune regulation that promote bystander suppression of effector T cells and infectious tolerance (Banchereau *et al.*, 2012). Although Tregs have mostly been shown to promote Th2 response in cutaneous leishmaniasis (CL) in human and mice (Tang and Bluestone 2008; Lund *et al.*, 2008; Rodriguez-Pinto *et al.*, 2012), some reports also suggest their involvement in controlling disease manifestation by facilitating timely homing of immune effector cells to the site of infection (Rodriguez-Pinto *et al.*, 2012). In VL such reports are lacking and more studies on human and mice are required to establish the role of Tregs. Moreover, it would be interesting to investigate the possible involvement of IL-35 producing T cells in VL as it was recently reported to play a Th2 promoting response in autoimmune diseases (Collison *et al.*, 2010). In the present review the initial part deals with the current understanding of the immunology of *Leishmania* infection and the dynamicity of the host pathogen interaction. We considered different evidences available to explain the immunoregulatory role of diverse immune cells and their cytokines with the course of infection in murine VL. It is an attempt to summarise the new concepts developed so far in terms of roles played by the different subsets of T cells, Th17 cells and their cytokines during disease.

These are followed by a concise description on modulation of signalling pathways by *L. donovani*. At the end, a brief description on the shortcomings in the study of immunology of VL and challenge to overcome the disease has been incorporated as future prospects.

Innate Immune Response

Infection with *Leishmania* begins when an infected female sand fly suck blood from its host. It has been found that few thousands of meta-cyclic promastigotes present in sand fly saliva are sufficient to establish disease progression causing wounding of the microvasculature that creates a hemorrhagic pool. Sand fly saliva contains well characterized molecules that have several activities, including vasodilation, inhibition of coagulation and immunomodulatory effects (Okwor *et al.*, 2009; Sacks D and Kamhawi S 2001). It also contains few uncharacterized molecules that could attract neutrophils and macrophages (Zer *et al.*, 2001) and recruit them to local inflammatory reaction (Kamhawi *et al.*, 2000).

Neutrophils

Neutrophils are the first cells to arrive at the site of *Leishmania* infection (Muller *et al.*, 2001), where they release neutrophil extracellular traps (NETs). NETs are composed of filamentous DNA with antimicrobial peptides and found to be induce by *Leishmania* surface proteins like GP63 and lipophosphoglycan (LPG) (Bhowmick *et al.*, 2008; Brinkmann *et al.*, 2004). In vitro experiments using human neutrophils and *Leishmania amazonensis* promastigotes have revealed that *Leishmania* are trapped and killed by NETs. Moreover *Leishmania braziliensis* elimination is dependent on the interaction between neutrophils and macrophages and was shown to be associated with tumor necrosis factor- α (TNF- α) as well as superoxide production. Co-operation between neutrophils and macrophages towards parasite elimination was also observed in experiments performed with *L. braziliensis* infected human cells (Bhowmick *et al.*, 2008; Brinkmann *et al.*, 2004; Guimaraes-Costa *et al.*, 2009).

However, neutrophils have proved to be beneficial for survival of *Leishmania* in infected tissues. Indeed, *Leishmania* have been found to extend lifespan of these cells where they can survive for hours to days after infection. The infected neutrophils secrete chemokines like CXCL8 (also known as IL-8) (Laufs *et al.*, 2002) and macrophage inflammatory protein (MIP)-1 β which play a critical role in attracting more neutrophils and macrophages, respectively, to the site of infection. These neutrophils when taken up by macrophages evade their antimicrobial responses leading to a 'silent' entry of these parasites into their host macrophages. (van Zandbergen *et al.*, 2004). Laskay and colleagues, (2003) coined a new term 'Trojan Horses' for neutrophils which help promastigotes to achieve this goal (Fig. 1). They observed that *L. major* promastigotes were readily phagocytosed by neutrophils *in vitro*, but survived within their phagosomes. The infected neutrophils were induced to undergo apoptosis and became a phagocytic meal for macrophages. As apoptotic neutrophils are phagocytosed through receptor-mediated pathways that fail to trigger macrophage defence responses, their cargoes of promastigotes are thereby efficiently and safely shuttled into the macrophage phagosomes (Laskay *et al.*, 2003; Ravichandran and Lorenz 2007). However, it has been shown in an *in situ* imaging study that most of the infected neutrophils rapidly engulfing promastigotes, are short-lived and release the parasites before being phagocytosed by the macrophages. Moreover, the observation that the parasite burden of macrophages and DCs isolated from the mice remains unchanged even after neutrophil depletion (Peters *et al.*, 2008), suggest that the neutrophils may merely scavenge the parasites that are otherwise ignored. Although neutrophils clearly participate in the early response to infection, their role as a "Trojan Horse" has yet to be confirmed.

Macrophages

Macrophages are the second wave of cells that enter the site of *Leishmania* infection. They serve as host for parasite replication and a source of cytokines modulating the T cell-mediated immune responses. Moreover, after appropriate activation by Th1 cells,

they act as effector cells for intracellular parasite killing. Promastigotes are rapidly phagocytosed by dermal macrophages (Locksley *et al.*, 1988) through a complement receptor (CR)-3 dependent mechanism (Mosser and Edelson 1985) and eventually metamorphose to amastigotes. In infected macrophages, amastigotes settle in acidic parasitophorous vacuoles that exhibit most of the features of phagolysosomes including the presence of lysosome markers such as lysosomal associated membrane protein (LAMP)-1, LAMP-2, and rab7p (small GTP-binding proteins involved in vesicular transport) (Dermine *et al.* 2005, Antoine *et al.*, 1999; Courre *et al.*, 2002). *Leishmania* parasites have evolved several mechanisms to avoid hydrolysis in the host innate environment. For example, *L. donovani* promastigotes inhibit the fusion of the phagosome with hydrolase-enriched endocytic organelles. This mechanism depends on the promastigote cell surface molecule lipophosphoglycan which prevents the formation of phagolysosome by disruption of lipid microdomains on the phagosome membrane (Dermine *et al.*, 2005).

Monocytes are attracted in the early stages of infection by products of sand fly saliva (Zer 2001) and later by chemokines such as MIP-1 β (van Zandbergen *et al.* 2004). *Leishmania* also produce chemotactic factors which induces the macrophages to secrete monocyte chemoattractant protein (MCP)-1 and CXCL1 (keratinocyte derived cytokines) that act as chemo-attractants for monocytes and neutrophils (Fig. 1). CCL2 is MCP-1 homolog in human macrophages (Deshmane *et al.* 2009; Racoosin and Beverley 1997; van Zandbergen *et al.* 2002). CCL2 can also attract other cells such as NK cells and DCs that are positive for the chemokine receptor CCR2. In human leishmaniasis, CCL2 and MIP-1 α appear to be responsible for macrophage activation in skin lesions (Ritter and Moll 2000). Macrophages stimulated by the synergistic action of CCL2 and IFN- γ kill parasites in localized CL (Muzio *et al.*, 2000), while the occurrence of IL-4 in diffused cutaneous leishmaniasis (DCL) lesions suppress CCL2 expression and promote progression of the disease. Therefore macrophages activated by chemokines play a pivotal role in bringing innate and

adaptive immune responses together during *Leishmania* infection.

Natural Killer (NK) Cells

NK cells come to the site of infection as early as 24 hours after parasite invasion and then migrate to the infected skin and draining LNs (Laskay *et al.* 1995). The migration of NK cells correlates with the expression of the NK cell-activating chemokine CXCL10. Moreover, treatment of susceptible BALB/c mice with recombinant CXCL10 results in significantly increased NK cell cytotoxic activity in the draining LN (Vester *et al.*, 1999). Previously NK cells were thought to be non-essential for the ultimate control of cutaneous leishmaniasis (CL) and VL as NK cell deficient mice could heal their lesions through IL-12 dependent IFN- γ production by CD4⁺T cells (Satoskar *et al.*, 1999). But recent research emphasizes NK cells as an important source of IFN- γ that can elicit antileishmanial activity in macrophages thereby mounting a protective Th1 response against the parasite (Bogdan 2012; Martin-Fontecha *et al.*, 2004). It has been shown that antigen specific CD4⁺ T cells are required for initiation of NK cell activation *in vivo* upon *L. major* infection (Bihl *et al.*, 2010) demonstrating a bidirectional regulation between innate and adaptive immunity.

Dendritic Cells (DCs)

Interaction of parasite reactive IgG with Fc γ receptors on DCs are essential for recognition and engulfment of *Leishmania* parasite. It appears that at later stages of infection, the balance between Fc γ R mediated induction of IL-12 from DCs and Fc γ R associated IL-10 release from infected macrophages is ultimately responsible for disease outcome (Filaridy *et al.*, 2010). MHC class I- and II-restricted antigen presentation towards both CD4⁺ and CD8⁺ T cells, respectively, by DCs is essential for appropriate T cell priming against parasite antigens. Infected DCs are crucial for T cell priming in CL, whereas infected macrophages mainly contribute to MHC class II-restricted CD4⁺ T cell restimulation (Kautz-Neu *et al.*, 2012). Mast cell primed DCs stimulate CD4⁺ T cells to release IFN- γ and IL-17, demonstrating that DCs promote Th1 and Th17 responses which are

protective against murine CL. Moreover, interaction of DCs with NKT cells determines Th1/Th2 differentiation (Dudeck *et al.*, 2011). DC derived IL-6 acts as a key cytokine regulating the expansion of CD4⁺CD25⁻FoxP3⁻IL-10⁺ T cells *in vivo* against *L. donovani* infection (Wiethe *et al.*, 2008; Stager *et al.*, 2006). *In vivo* studies on mice have shown that CD11c^{hi} DCs, as well as a mixed CD11c^{int/lo} cell population, are capable of inhibiting host resistance and promoting disease-associated pathology in murine VL (Owens *et al.*, 2012). Furthermore IL-10⁺IL-27⁺ DCs are able to promote IL-10 production by Th1 cells (Awasthi *et al.*, 2008) thereby emphasizing the importance of CD11c⁺ cells in priming of Th1 and Th17 subsets, subsequently as a potential target for immunotherapy.

During cure in VL, IFN- γ secreting neutrophil, eosinophil and NK cells increase, accompanied by increase in IL-12 producing monocytes. There is a clear correlation between cytokine profile of the innate immune cells and VL pathology, indicating their pivotal role not only in the control of early parasite growth and systemic spreading of *Leishmania*, but also as relevant source of immunoregulatory cytokines. The co-ordination of innate immune response with adaptive immunity acts as a major relevance for both control of parasitism and morbidity (Peruhype-Magalhaes *et al.*, 2005). Thus, the innate immune cells may, in addition to other factors, contribute significantly in regulating T-cell response and cytokine microenvironment during disease progression and are critical additive to adaptive immunity for controlling the disease outburst.

Adaptive Immunity

Chemokines may have a direct role in the development of the IFN- γ mediated Th1 response. *L. donovani* infected mice lacking CCR5 or its ligand MIP-1 α , demonstrate a low antigen-specific IFN- γ response during the early phases of infection. MIP-2 and CXCL1, the functional murine homologs of human IL-8, are rapidly produced in the skin by the *L. major* infected macrophages which serve to recruit neutrophils and DC at the site of infection (Modi and

Yoshimura 1999; Racoosin and Beverley 1997). In murine VL, infected mice undergo a rapid hepatic accumulation of MIP-1 α , CCL2 and CXCL10 (Cotterell *et al.*, 1999). Increased expression of CXCL10 enables accelerated liver granuloma formation and inflammatory response against the parasite. Monocytic cells attracted by MIP-1 α and CCL2, following IFN- γ stimulation, could be the source of Th1-mobilizing chemokines such as CXCL10 (Farber, 1997). Unlike liver cells, spleen cells from *L. infantum* infected mice produce both Th1- and Th2-type cytokines with the Th2-type response being dominant. This is compatible with the sustained expression of CCL2 rather than CXCL10, thereby show an influx of macrophages rather than T cells in the spleen (Rousseau *et al.*, 2001). This perhaps is the reason for parasite persistence in the spleen whereas liver usually controls the infection (Kaye *et al.*, 2004). Hence, chemokines are crucial both as chemoattractant for innate immune cells, and in promoting early cell mediated immune responses during VL in both human and mice.

Th1 and Th2 Cells

Higher TNF- α , IFN- γ , IL-12, IL-4, and IL-10 levels were observed in patient serum with active lesions, whereas cured subjects produced only IFN- γ at elevated levels. These observations suggest the presence of a mixed Th1/Th2 response during active CL and a sustained Th1 response characterized by elevated IFN- γ levels, and down-regulation of IL-4 and IL-10 production while cure (Castellano *et al.*, 2009; Kedzierski *et al.*, 2008). In human, VL is associated with increased production of multiple and primarily pro-inflammatory cytokines and chemokines. Patients have been found to have elevated plasma protein levels of IL-1, IL-4, IL-10, IL-6, IL-8, IL-12, IL-15, IFN- γ inducible protein-10 (IP-10), IFN- γ , and TNF- α (Alvar *et al.*, 2012; Ansari *et al.*, 2006; Kurkjian *et al.*, 2006; Nylen and Sacks 2007). Elevated levels of IL-10 and TGF- β have been shown from PBMC of active VL patient (Saha *et al.*, 2006; Hailu *et al.*, 2004). With treatment, IL-10 slowly decreases while IFN- γ increases in liver and spleen and attain their normal levels (Costa *et al.*, 2012). Elevated levels of IFN- γ mRNA have been

found in target organs, such as the spleen and bone marrow, during the acute phase of infection, accompanied by increased levels of IL-10 (Nylen *et al.*, 2007; Nylen and Sacks 2007; Banerjee *et al.*, 2008). Some intriguing studies suggest that the pro-inflammatory cytokines are not depressed rather they are unresponsive to the stimuli of pro-inflammatory cytokines (Hailu *et al.*, 2004). The underlying causes of such immunologic unresponsiveness remain a subject of further investigation. Additionally the development of VL in human is not driven by Th2 skewing per se but some unexploited mechanisms may also contribute to the pathogenesis of the disease.

IL-10, which has been suggested to be induced by high levels of TNF- α (Ato *et al.*, 2002) may serve to control the tissue damage caused by TNF- α . But at the same time IL-10, secreted from macrophages, promotes parasite persistence by inhibiting macrophage activation (Murray 2002). IL-10 is a regulatory cytokine, presumed to be induced as a part of homeostatic network to protect tissue from collateral damage caused by excessive inflammation. Primarily it has suppressive effects on immune function, targeting multiple activation and antigen presentation pathways of macrophage and DC. It renders macrophage unresponsive to activation signals and acts on DCs causing them to down regulated CCR7 and thereby losing migratory capacity preventing them from proper access of T cell areas and effective priming of T cell responses (Ato *et al.*, 2002). Moreover, treatment with pentavalent antimonials could inhibit IL-10 production leading to rapid granuloma formation and parasite killing with subsequent increase in IFN- γ production from Th1 cells. This is followed by enhanced expression of IL-12, NO and inducible nitric oxide synthase (iNOS) in infected tissue further enhancing effectiveness of the drugs (Buxbaum *et al.*, 2013; Murray *et al.*, 2003; Hailu *et al.*, 2004; Banerjee *et al.*, 2008).

IFN- γ , the most important cytokine for Th1 response, is likely to be produced in lymphoid organs where *Leishmania* proliferates. IFN- γ along with IL-12 has potential therapeutic efficacy and may enhance vaccine efficiency. Immunotherapy with IFN- γ /IL-12

prior to the infection restricts the early phase of the infection in CL (Ota *et al.* 2008). Vaccination against a progressive *L. donovani* infection could increase the production of IFN- γ , IL-12 and NO and downregulate IL-4 secretion thereby resulting in decrease of parasite burden in liver and spleen (Bhowmick and Ali 2009; Mazumdar *et al.*, 2004). Similar results were also obtained by IFN- γ immunotherapy manifesting an enhanced Th1 response accompanied with down regulation of disease promoting IL-4 and IL-10 (Bhowmick *et al.*, 2007).

IFN- γ may act as a double edged sword while it can stimulate macrophages and limit amastigote replication when coupled with lipopolysaccharides, it also promote amastigote survival and growth when coupled with TNF- α (Colmenares *et al.*, 2002; Qi *et al.*, 2004). Thus, IFN- γ may play a bidirectional role at the level of parasite-macrophage interactions. It has a protective effect against infection when optimally associated with other factors such as IL-12 and NO and in the absence of such synergy it promotes amastigote growth.

Accumulating reports from mouse model of nonhealing or disseminating forms of leishmaniasis has reinforced pathogenic mechanisms that take into account the presence of parasite-driven Th1 responses suppressed either in magnitude or function by IL-10 (Anderson *et al.*, 2009). In mice, activated *Leishmania* specific CD4⁺ T cells are detected in draining LN as early as 16 h after infection. These cells rapidly expand and differentiate into cytokine secreting cells (Malherbe *et al.*, 2000). Majority of *Leishmania* specific CD4⁺ T cells differentiate into Th1 cells that secrete IFN- γ and/or TNF- α which efficiently contribute to the parasite elimination through different mechanisms including the activation of macrophage. In contrast, genetically susceptible BALB/c mice show T cell response dominated by Th2 cells that secrete IL-4, IL-10, IL-5, and / or IL-13. IL-4 initiates induction of Th2 differentiation during progressive leishmaniasis in resistant mice but may display beneficial responses in *L. major* susceptible BALB/c mice. IL-4 is crucial in priming CD8⁺ T cells and protection against VL during

vaccination. IL-4 has major role in differentiation and activation of CD4⁺ T cells, B cells and macrophage during infection (Biedermann *et al.*, 2001; Ghalib *et al.*, 1993; Stager *et al.*, 2003). Infection with *Leishmania* also results in the activation and expansion of parasite specific CD8⁺ T cells. Upon infection expansion of T cells and their rapid recruitment to lymph nodes as well as the restriction of IL-13 and IL-10 production leading to higher IFN- γ /IL-10 ratio play an important role in protection against *Leishmania*.

Central Versus Effector Memory Cells

Memory cells have been broadly classified into two types-central and effector. Central memory cells home to primary lymphoid organs and proliferate to perform effector function only after secondary stimulation. In contrast, effector memory cells do not proliferate but secrete effector cytokines due to antigenic stimulation (Lanzavecchia and Sallusto 2005). Central memory CD4⁺ T cell population generated during *L. major* infection is capable of developing into either Th1 or Th2 effectors. Under the influence of IL-12, *Leishmania* specific central memory CD4⁺ T cells get differentiated into IFN- γ producing Th1 cells (Pakpour *et al.*, 2008). Low dose *L. major* promotes a transient Th2 response that is downregulated by IFN- γ producing CD8⁺ T cells which may contribute to rapid resolution of secondary lesions (Uzonna *et al.*, 2004; Wang *et al.*, 1993). It has been reported that *L. donovani* infection augments vaccine induced immunity to *Listeria*, enhancing the host protective antigen specific memory CD8⁺ T cell responses (Polley *et al.*, 2005). In VL, generation of antigen specific effector memory responses help in protection against the disease by proliferation and augmentation of CD62L⁻CD127⁺ CD4⁺/CD8⁺ T cells (Mazumder *et al.*, 2011a; Ravindran *et al.*, 2012; Roychoudhury *et al.*, 2011; Mazumder *et al.*, 2011b; Mazumder *et al.*, 2010; Bhowmick *et al.*, 2008; Mazumdar *et al.*, 2004). It appears that effector memory responses are more crucial than central memory response for protection against VL but further studies are required to clarify their roles.

Th17 Cells

It was Harrington *et al.*, (2005) who first reported the presence of IL-17 (Harrington *et al.*, 2005) and classified Th17 subset as another member of CD4⁺T cell lineage. The development of Th17 cells as a distinct population from CD4⁺T cells is controlled by a combination of cytokines like IL-6, IL-21, IL-23, IL-1 β and TGF- β (Acosta-Rodriguez *et al.*, 2007; Chen *et al.*, 2007; Liu and Rohowsky-Kochan 2008). IL-23 is essential for generation and establishment of IL-17 producing CD4⁺ T whereas TGF- β and IL-6 are required for their priming (Cruz *et al.* 2006, Bettelli *et al.*, 2006; Mangan *et al.*, 2006). Cytokine-driven activation of the signal transducer and activator of transcription (STAT) 3 pathway is an essential step in Th17 cell differentiation (Holland *et al.*, 2007). This leads to the activation of a cascade of transcription factors such as retinoid-acid receptor-related orphan receptor- γ (ROR- γ), chemokine (C-C motif) receptor 6 (CCR6), Interferon regulatory factor (IRF) 4, basic leucine zipper transcription factor (BATF), FOXP3, T-bet, peroxisome proliferator activated receptor (PPAR) γ , Fatty acid binding protein and suppressor of cytokine signalling (SOCS) protein (Hwang *et al.*, 2010). Among them CCR6 and ROR- γ are well studied markers for the identification of Th17 cells (Hirota *et al.*, 2007).

Initially reports from murine CL suggested the role of Th17 similar to Th2 responses as IL-17 was observed to synergise with TGF- β in increasing parasite load and disease pathology (Santarlaschi 2009; Bacellar 2009; Cezario 2011; Manel 2008). But as studies progressed, Th17 response has emerged as an additive to Th1 response which promotes initiation of inflammatory response through neutrophil chemotaxis and NO production (Reinhard *et al.*, 2011; Dudeck *et al.*, 2011). This ultimately helps in reducing parasite burden in CL, PKDL, VL of mice and human. Other members of Th17 subset like IL-22 and IL-23, along with IL-17, also play a significant role in protection against different forms of leishmaniasis like VL, CL, MCL, American tegumentary leishmaniasis, PKDL and various other diseases like tuberculosis, lung infection and rheumatoid arthritis (Pitta *et al.*, 2009; Khader *et al.*,

2007; Katara *et al.*, 2012; de Assis *et al.*, 2013; Ghosh *et al.*, 2013). Suppression of IL-17 by IL-10 and IL-27 during *Leishmania* infection (Anderson *et al.* 2009; Gonzalez-Lombana *et al.*, 2013; Owens *et al.*, 2012) furthermore supports the association of IL-17 with disease alleviation. Additionally, exacerbation of *Leishmania* suppresses LPS induced IL-17 production due to rise in Th2 responses (Lapara NJ 3rd and Kelly 2010). IL-17 being a promoter of Th1 response has been used in a combination with vaccine and drugs for improving their effectiveness. Injection of recombinant IL-17 with curdlan enhances its therapeutic effect, thereby causing a marked increase in generation of IFN- γ along with NO and a significant suppression of the organ parasite burden during murine VL (Ghosh *et al.*, 2013). CpG DNA vaccine in the presence of live *L. major* causes activation of neutrophil which leads to specific induction of Th17 cells for IL-17 secretion leading to enhancement in the development of a protective cellular immunity against the parasite (Wu *et al.*, 2010). Even in the absence of Th1 response, Th17 shows some protection against leishmaniasis through an unconventional pathway for activating effector T cell responses (Pitta *et al.*, 2009; Soong *et al.*, 2012). In addition to Th17 cells, IL-17 is shown to be secreted from other cells like B cells, CD8⁺ T cells, $\gamma\delta$ T cells and neutrophils as well (Bermejo *et al.*, 2013; Li *et al.*, 2010). IL-17, secreted from CD8⁺ cells is demonstrated to participate in the inflammatory response to mucosal leishmaniasis (Boaventura *et al.*, 2010).

It is intriguing to note that Th17 cells have close developmental link with CD4⁺ FOXP3⁺ regulatory T cells (Tregs). FOXP3 and ROR- γ can directly interact via a DNA-independent mechanism, and during Th17 cell development FOXP3 is transiently expressed (Zhou *et al.*, 2008). There are increasing evidences for the existence of FOXP3⁺ cells that could secrete IL-17 (Ayyoub *et al.*, 2009; Kryczek *et al.*, 2011). Recent studies in murine CL advocate a role of CCR6 in Treg cell rather than Th17 cell recruitment during parasitic infections which depends on cell-mediated immune response as the predominant protective immune mechanism (Barth *et al.*, 2012). Further, it is shown that a balance

between Treg and IL-17 control hepatic immune responses. Increase in either of these two will lead to parasite susceptibility (Zhao *et al.*, 2010). But how these two populations are interacting with each other and whether their collective effect or individual contribution is crucial for disease regression could be a topic for future investigation.

Regulatory T Cells

Regulatory T cells are divided into “natural (or constitutive)” and “induced (or adaptive)” Treg cells, which may have complementary and overlapping functions in immune regulation. Natural Treg (nTreg) cells are developed in the thymus whereas inducible Tregs (iTregs) are derived from the periphery under the influence of DCs (Sakaguchi *et al.*, 2010) and can be either CD4⁺CD25^{+/-} or CD8⁺CD25^{+/-}. IL-10 secreted from APCs such as DCs or macrophages in the periphery induce naïve T cells to become FOXP3⁺ Treg cells. This subset of regulatory cells secretes IL-10 for active participation in immuno-modulation and termed as Tr1 cell (Groux *et al.*, 1997).

Additionally, TGF- β secreted from APCs can induce the transformation of naïve T cells to a TGF- β secreting Treg cells known as Th3 cells (Bilate and Lafaille 2012). These two sub sets (*viz.* Tr1 and Th3) of T cells are indispensable for maintaining immune homeostasis. Studies on the mechanism of action and phenomenology of different types of Tregs (Roncarolo *et al.*, 2006; Workman *et al.*, 2009) as well as immune regulation by other T cell populations like CD8⁺ T cells (Chang *et al.* 2002), CD4⁺CD8⁻ T cells (Zhang *et al.* 2000), $\gamma\delta$ T cells (Hayday and Tigelaar 2003) could help us in understanding the mechanism involved in immunosuppression.

Treg cells are professed to use many cellular processes to control immunosuppression. Critical of them are two core phenomena known as bystander suppression and infectious tolerance. Suppressive activity of Treg cells requires their prior activation through their T cell receptors. Once potentiated, Treg cells can induce immuno-suppression in an antigen-nonspecific way called ‘bystander suppression’ (Qin *et al.*, 1993). Thus, Treg cells with one antigen specificity can suppress T effector cells with many

other distinct antigen specificities (Wing and Sakaguchi 2010). By infectious tolerance, one population of suppressor T cells create a regulatory milieu that promotes the outgrowth of a new population of Treg cells with antigen specificities distinct from those of the original Treg population. This tolerant state induced by Treg cells is maintained even after loss or removal of the original Treg cell population (Qin *et al.*, 1993; Sakaguchi *et al.*, 2010; Tarbell *et al.*, 2007). Thus, through the processes of bystander suppression and infectious tolerance, Treg cells effectively maintain a state of stable tolerance and immune regulation.

Several examples are there demonstrating the immunosuppressive role of Treg cells in autoimmune and infectious diseases, such as arthritis (Chen *et al.*, 2013), type-1 diabetes (Ryba-Stanislawowska *et al.*, 2013), asthma (Nawijn *et al.*, 2013), HIV (Li *et al.*, 2013) and tuberculosis (Sharma *et al.* 2009; Ebinuma *et al.*, 2008). Studies of suppressive cells in leishmaniasis go back to early 1970s when Bryceson reported the emergence of antigen-specific immune suppression during *Leishmania* infection (Bryceson 1970). It was further extended by Arredondo *et al.* that the spleen cells from infected animal suppressed normal lymphocytes (Arredondo and Perez, 1979) and Howard *et al.* who tried to characterize suppressive T cell in murine models of *L. tropica* infection (Howard *et al.*, 1980; Howard *et al.*, 1981). Association of B cells with the development of suppressive T cell (Sacks *et al.*, 1987) and their active involvement against both the inductive and expressive phases of DTH response in CL were reported (Dhaliwal *et al.*, 1985). A potentially novel immunoregulatory role for CD8⁺ T cells following DNA vaccination has been reported in the last decade (Gurunathan *et al.*, 2000). Our unpublished work on murine VL also indicates the existence of CD8⁺CD25⁺FOXP3 cells as potential regulatory cells through secretion of IL-10 during the development of the disease. CD8⁺ cells eliciting IL-10 have been found to possess remarkable immunosuppressive activity in autoimmune and infectious diseases (Noble *et al.*, 2006). Since 1995 when Sakaguchi and colleagues defined CD4⁺ CD25⁺ cells as the most important population of regulatory cells (Sakaguchi

et al., 1995), the attention of studying Treg cells has been restricted mainly to this population. CD4⁺CD25⁺ regulatory T cells suppress both Th1 and Th2 cells and these regulatory T cells have a profound therapeutic potential against CL (Rodrigues *et al.*, 2013). Reports have recognized the involvement of CD4⁺CD25⁺ Tregs in progression of CL caused by both *L. major* (Belkaid *et al.*, 2002) and *L. amazonensis* in mice (Ji *et al.*, 2005) and *L. braziliensis* in humans (Campanelli *et al.*, 2006). Treg cells show suppressive role against human acute and chronic CL by way of secreting IL-10 and suppressing IFN- γ (Bourreau *et al.*, 2009). With healing of CL, the frequencies of CD4⁺CD25^{hi}CD127 Treg cells increased, showing their contribution in the resolution of chronic dermal lesions (Tang *et al.*, 2008). During *L. infantum* infection in BALB/c mice, enrichment of CD4⁺CD25⁺FOXP3⁺ Treg cells have been shown in the draining lymph nodes and spleen cells (Rodrigues *et al.*, 2009) suggesting their association with the disease. Involvement of CD4⁺CD25⁺ Treg cells in progression of human VL and PKDL has also been reported (Saha *et al.*, 2007; Katara *et al.*, 2011). In PKDL a correlation of nTreg cells both with IL-10 levels and parasite burden emphasize their role in disease severity (Katara *et al.*, 2011). Interestingly, reports from both human and murine CL suggest an association between increased frequencies of CD4⁺CD25^{hi}CD127 Treg cells and resolution of dermal lesions (Saha *et al.*, 2007; Ji *et al.*, 2005) thereby indicating the contribution of Treg cells towards cure of CL.

Till date the role of Tregs as the primary source of IL-10 is controversial. It has been shown in human VL that rather than FOXP3⁺ T cells, Tr1 cells are the major IL-10 producing cells and they are important in suppressing antileishmanial immunity and conditioning host macrophage for enhanced parasite survival and growth (Nylen *et al.*, 2007; Stager *et al.*, 2006; Anderson *et al.*, 2009; Maurya *et al.*, 2010). But recent reports advocate CD4⁺CD25⁺FOXP3⁺ cells as the major source of IL-10 in human VL having high potential to suppress antileishmanial immune responses (Rai *et al.*, 2012). Similar observations have also been made recently by Tiwanathagorn *et al.*, 2012 that CD4⁺FOXP3⁺ Treg cells induce IL-10

mediated *L. donovani* persistence in murine VL (Tiwanathagorn *et al.*, 2012).

Thus detailed investigations are required regarding the immunosuppressive role played by different regulatory T cell populations (viz., Tr1, Th3, nTregs, iTregs and other cells) and the source(s) of IL-10 for disease pathogenesis. Understanding the nature of the major immunoregulatory cells and their mechanism during leishmaniasis may not only unlock new avenues towards novel target but also lead to better intervention for disease cure.

Friends and Foes Among the Members of IL-12 Family

IL-12 family consists of heterodimeric cytokines, with several distinctive features. It has many molecular and functional characteristics that provide unique opportunities for positive and negative feedback control. Chain pairing promiscuity is a common feature of this group's member which includes IL-12, IL-23, IL-27 and IL-35 (Collison and Vignali 2008; Jones and Vignali 2011). Despite many structural similarities of these cytokines, their receptors and downstream signalling components, they have very different biological activities that challenge their symphony. IL-12 and IL-23 are mainly proinflammatory cytokines with key roles in the development of the Th1 and Th17 subsets of T cells, respectively (Kastelein *et al.*, 2007; Pflanz *et al.*, 2002, Langrish *et al.*, 2004). On the other hand IL-27 and recently identified IL-35 are known to play regulatory roles both in human and mice (Collision *et al.*, 2010; Wojno and Hunter, 2012; Murugaiyan *et al.*, 2009; Perona-Wright *et al.*, 2012; Collison, 2007; Vignali *et al.*, 2008). These observations establish a functionally balanced dichotomy in this family, with IL-12 and IL-23 being positive and IL-27 and IL-35 as negative regulators.

IL-12, the most extensively studied member of this family is a key pro-inflammatory cytokine and effective stimulant for the induction of an IFN- γ mediated Th1 response during VL. Phagocytic cells like monocytes, macrophages, neutrophils and DCs are the major source of IL-12 production (Scott P

2003; Chan *et al.*, 2006; dos Santos *et al.*, 2008; Zaph and Scott P 2003). IL-12 has a central role in generating strong Th1 response with elevation in IFN- γ level in both murine and human VL (Saha *et al.*, 2007; Banerjee *et al.*, 2008; Zhang *et al.*, 2013). Susceptibility to experimental *L. mexicana* infection was also attributed to IL-12 insensitiveness (Rodriguez-Sosa *et al.*, 2001). Similar observations were made in human CL as well where IL-12 unresponsiveness was reported to be responsible for the persistence of infection (Bourreau *et al.*, 2001). With the progression of disease, Th1 response decreases and suppressive cytokines like IL-4, IL-10 and TGF- β increase promoting Th2 response. In the absence of IL-12, increase in parasite load is accompanied by decrease in IFN- γ , TNF- α and iNOS production (Adhikari *et al.*, 2012). During successful therapy and vaccination, IL-12 promoting Th1 response corresponds with increase in IFN- γ and NO production leading to downregulation of Th2 responses accompanied by reduction in parasite burden (Bhowmick *et al.*, 2009; Mazumdar *et al.*, 2004). It has also been reported that even in the absence of IFN- γ , IL-12 strongly promotes healing (Murray *et al.*, 2000; Adhikari *et al.*, 2012; Satoskar *et al.*, 2000) emphasising indispensability of IL-12 in the induction of protective immunity against VL.

Another important and widely studied member of this family is IL-27. It is an ongoing debate that whether IL-27 drives a Th1 response or has a pleiotropic effect on Th1, Th2 and Th17 as a key regulatory cytokine that controls the balance between immunity and pathology and their regulation (Anderson *et al.*, 2009; Hunter *et al.*, 2004). Both the hypotheses are supported by adequate evidences. IL-27 has been shown to be critical for differentiation and timely initiation of efficient anti-parasite Th1 immunity with enhanced IFN- γ during infection (Kamiya *et al.*, 2004; Takeda *et al.*, 2003; Zahn *et al.*, 2005). Potential contribution of IL-27 along with IL-17 in the control of *L. braziliensis* infection (Novoa *et al.*, 2011) by suppressing Th2 response (Yoshimoto *et al.*, 2007) has been shown. But recent studies suggest IL-27 as a protective cytokine which promotes antitumor immunity (Natividad *et al.*, 2013) as well as acts as a potent Th2 cytokine which

promotes tumor growth by inducing Treg cell differentiation (Hunter and Kastelein 2012; Hall *et al.*, 2012; Murugaiyan and Saha 2013). Enhanced plasma level of IL-27 both in human and mice during healing and non-healing CL further support this hypothesis (Tolouei *et al.*, 2012).

In VL, significantly elevated levels of IL-27 at both mRNA and plasma of VL patients suggested it as a strong Th2 cytokine (Ansari *et al.*, 2011). Augmentation of IL-27 along with IL-21 leads to expansion of IL-10 thereby causing disease progression and parasite persistence. IL-27 has also been reported to be involved in mediating susceptibility to *L. donovani*, through interaction with its T cell cytokine receptor (Rosas *et al.*, 2006).

Several recent studies have shown IL-27 to mediate anti-inflammatory activity through its ability to suppress Th17 cells (Batten *et al.*, 2006; Stumhofer *et al.*, 2006) and induction of IL-10 from activated CD4⁺ T cells. It is now being accepted that IL-27 is critical for the generation of IL-10 producing CD4⁺T cells *in vitro* (Awasthi *et al.*, 2007; Fitzgerald *et al.*, 2007; Stumhofer *et al.*, 2007), via signalling pathways dependent on STAT3. Optimal production of IL-27 requires co-ordination of c-Maf (Musculoaponeurotic Fibrosarcoma a proto-oncogene), inducible co-stimulator (ICOS) and IL-21 expression (Apetoh *et al.*, 2010). Emerging evidences also suggest that IL-27 may directly alter methylation patterns around the *il10* promoter in CD4⁺T cells, thus allowing greater IL-10 expression (Hedrich *et al.*, 2010). IL-27 also favours the production of IL-10 by IFN- γ producing Th1 cells through an alternate signalling pathway that involves STAT1, STAT4 and Notch (Batten *et al.*, 2008; Rutz *et al.*, 2008).

IL-35, a recently identified member, produced by thymus-derived Treg cells has been reported to be one of the potent regulatory cytokine in autoimmune disease both in human and mice (Collison *et al.*, 2010; Collison *et al.*, 2007; Vignali Collison *et al.*, 2008). IL-35 association has been shown with atherosclerosis (Lin *et al.*, 2012), hepatitis B (Liu *et al.*, 2011); leukemia (Wu *et al.*, 2012), and tumor (Olson *et al.*, 2012; Wang *et al.*, 2013), but its

regulatory role in infectious diseases is yet to be established. Association of IL-35 with the progression of VL may lead to new targets for better intervention and control of the disease.

Modulation of Signalling Pathways by *L. donovani*

Leishmania dampens host cell immune response by modulating several key signalling pathways such as nuclear factor- κ B (NF- κ B) and janus kinase (JAK)-signal transducer and activator of transcription (STAT) dependent pathways. NF- κ B has a critical role in initiating innate immune response and in protective Th1 mediated immunity. The *Leishmania* parasite has been observed to evade NF- κ B activation in infected macrophage and/or DC by promoting cleavage of its RelA sub unit. As a result production of pro-inflammatory cytokines and antimicrobial mediators such as iNOS is inhibited that allows parasite survival and persistence within the host cell (Reinhard *et al.* 2012). *L. donovani* infection modifies NF- κ B signalling by causing a specific cleavage of p⁶⁵RelA subunit. p³⁵RelA, a cleavage fragment of p⁶⁵RelA then migrates to the nucleus and binds to DNA as a heterodimer with NF- κ B p⁵⁰. p³⁵RelA/p⁵⁰ dimer alters the transcription of several pro-inflammatory cytokine and chemokine genes, thereby subverting macrophage's effector functions (Gregory *et al.* 2008). Modulation of JAK/STAT pathway by *L. donovani* attenuates IFN- γ dependent macrophage response. In addition, it downregulates IFN- γ protein receptor expression and upregulate a transient expression of SOCS3 protein, a negative regulator of IFN- γ signaling. Amastigote form of the parasite has been reported to hinder nuclear translocation of STAT1 α in response to IFN- γ and compromises STAT1 α -nuclear transport adaptor importin- α 5 interaction (Matte and Descoteaux 2010). Together, modulation of these two pathways results in downregulation of Th1 response with enhanced survivability of the parasite.

Future Prospects

VL is a neglected tropical disease with a complex immune mechanism. It remains a challenge to understand its biology. Host immune defence mechanism, triggered by the bite of sand fly, recruits




Fig. 1: Host immune response against *L. donovani*. With the parasite entry polymorphonuclear neutrophils (PMNs) and macrophages (MΦs) are recruited at the site of infection and promastigotes are engulfed into phagosomes. Neutrophils, secrete chemoattractants, CXCL-1, MIP-1 β and CXCL-8 to engage more PMNs, MΦ and other immune cells. MΦ actively take up parasites either from fresh inoculum or released from PMN. They may also take up PMNs containing phagocytosed promastigotes surviving as Trojan horses. Chemoattractants, CCL-2 and CXCL-10 secreted by MΦ activate DCs and NK cells respectively, for generation of various anti-leishmanial responses, such as NK cell-mediated IL-12 secretion, and mast cell (MC) primed DC-induction of CD8⁺ cells for cytotoxicity. CD4⁺ cells under the influence of IL-12, IFN- γ , IL-10 and TGF- β cytokines from MΦ and DCs differentiate to give rise to (i) IFN- γ and TNF- α secreting Th1 cells (ii) IL-17 secreting Th17 cells (iii) IL-4 and IL-13 producing Th2 cell and (iv) IL-10 and TGF- β producing Treg cells for parasite clearance/survival

neutrophils and macrophages followed by NK cells and DCs for the phagocytosis of the parasite. But the mechanism involved in the establishment of *L. donovani* infection and how these responses fail to control the parasite propagation is not well

understood. Currently, the Trojan horse concept explaining parasite survival within the neutrophils during *L. major* infection could provide an answer, but contradictory reports exist regarding its role in protective response against infection. Moreover, there is no such report available for its involvement in VL. The understanding of the involvement of chemokines as chemoattractants and cytokines to abridge innate and adaptive immunity is important in *Leishmania* infection. Studying the role of these chemokines in clearing *L. donovani* parasites and modulating the immune response against the parasite may unravel future targets for immunotherapy. Among the cytokines, IFN- γ is crucial for priming protective Th1 responses, and along with IL-12, suppresses Th2 cytokines like IL-10 and IL-4. Nevertheless, there is a lacuna in the use of such knowledge for the development of contemporary approaches towards combating the disease. Although IL-10 is proven to be the principal cytokine involved in VL pathology, and the use of anti IL-10 antibodies remains one of the potent forms of immunotherapy against this disease, contradiction still exists regarding its source(s). Moreover, our understanding of the role of different immune cells and their mechanism of action against VL is still unclear. Although Tregs have

emerged as the most important cellular subset responsible for disease pathogenesis, their nature and mode of action for regulating the immune response remains elusive. Recent research suggests Th17 as an additive to Th1 response, but to what extent this is true in controlling VL is unanswered. Involvement of TGF- β in both Th17 cell priming and development of Treg could also be looked upon as an important issue. Members of IL-12 family are exceptionally versatile, consisting of three α and two β chains, of which one α and one β chain combine to give highly diverse cytokines which could act in antagonism or synergism in the generation of Th1 response. Studying their unexploited combinations could lead to the discovery of new cytokine networks and prospective immunotherapeutic targets to combat the disease.

Acknowledgements

This work was supported by grants from the Council of Scientific and Industrial Research and the Indian Council of Medical Research, Government of India. The authors thank Mr. Pradyot Bhattacharya, Mr. Md Shadab, Mr. Somsubhra Thakur Choudhury, and Mr. Sarfaraz Ahmad Ejazi for correcting the manuscript and Mr. Shameel Iqbal for helping in drawing the figure.

References

- Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A and Sallusto F (2007) Interleukins 1 β and 6 but not transforming growth factor- β are essential for the differentiation of interleukin 17-producing human T helper cells. *Nat Immunol* **8** 942-949
- Adhikari A, Gupta G, Majumder S, Banerjee S, Bhattacharjee S, Bhattacharya P, Kumari S, Haldar S, Majumdar SB, Saha B and Majumdar S (2012) Mycobacterium indicus pranii (Mw) re-establishes host protective immune response in *Leishmania donovani* infected macrophages: critical role of IL-12. *PLoS One* **7** e40265
- Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M and Team WHOLC (2012) Leishmaniasis worldwide and global estimates of its incidence. *PLoS One* **7** e35671
- Anderson CF, Stumhofer JS, Hunter CA and Sacks D (2009) IL-27 regulates IL-10 and IL-17 from CD4⁺ cells in nonhealing *Leishmania major* infection. *J Immunol* **183** 4619-4627
- Ansari NA, Kumar R, Gautam S, Nylén S, Singh OP, Sundar S and Sacks D (2011) IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis. *J Immunol* **186** 3977-3985
- Ansari NA, Saluja S and Salotra P (2006) Elevated levels of interferon- γ , interleukin-10, and interleukin-6 during active disease in Indian kala azar. *Clin Immunol* **119** 339-345
- Antoine JC, Lang T, Prina E, Courret N and Hellio R (1999) H-2M molecules, like MHC class II molecules, are targeted to parasitophorous vacuoles of *Leishmania*-infected macrophages and internalized by amastigotes of *L. amazonensis* and *L. mexicana*. *J Cell Sci* **112** 2559-2570
- Apetoh L, Quintana FJ, Pot C, Joller N, Xiao S, Kumar D, Burns EJ, Sherr DH, Weiner HL and Kuchroo VK (2010) The aryl hydrocarbon receptor interacts with c-Maf to promote

- the differentiation of type 1 regulatory T cells induced by IL-27. *Nat Immunol* **11** 854-861
- Arredondo B and Perez H (1979) Alterations of the immune response associated with chronic experimental leishmaniasis. *Infect Immun* **25** 16-22
- Ato M, Stager S, Engwerda CR and Kaye PM (2002) Defective CCR7 expression on dendritic cells contributes to the development of visceral leishmaniasis. *Nat Immunol* **3** 1185-1191
- Awasthi A, Carrier Y, Peron JP, Bettelli E, Kamanaka M, Flavell RA, Kuchroo VK, Oukka M and Weiner HL (2007) A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. *Nat Immunol* **8** 1380-1389
- Awasthi A, Murugaiyan G and Kuchroo VK (2008) Interplay between effector Th17 and regulatory T cells. *J Clin Immunol* **28** 660-670
- Ayyoub M, Deknuydt F, Raimbaud I, Dousset C, Leveque L, Bioley G and Valmori D (2009) Human memory FOXP3+ Tregs secrete IL-17 *ex vivo* and constitutively express the T(H)17 lineage-specific transcription factor RORgammat. *Proc Natl Acad Sci U S A* **106** 8635-8640
- Bacellar O, Faria D, Nascimento M, Cardoso TM, Gollob KJ, Dutra WO, Scott P and Carvalho EM (2009) Interleukin 17 production among patients with American cutaneous leishmaniasis. *J Infect Dis* **200** 75-78
- Banchereau J, Pascual V and O'Garra A (2012) From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. *Nat Immunol* **13** 925-931
- Banerjee A, De M and Ali Nahid (2008) Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses *J Immunol* **181** 1386-1398
- Barth T, Schmidt D, Botteron C, Nguyen TT, Ritter U, Mannel DN and Lechner A (2012) An early reduction in Treg cells correlates with enhanced local inflammation in cutaneous leishmaniasis in CCR6-deficient mice. *PLoS One* **7** e44499
- Batten M, Kljavin NM, Li J, Walter MJ, de Sauvage FJ and Ghilardi N (2008) Cutting edge: IL-27 is a potent inducer of IL-10 but not FoxP3 in murine T cells. *J Immunol* **180** 2752-2756
- Batten M, Li J, Yi S, Kljavin NM, Danilenko DM, Lee J, de Sauvage FJ and Ghilardi N (2006) Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. *Nat Immunol* **7** 929-936
- Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udey MC, Wynn TA and Sacks DL (2001) The role of interleukin (IL)-10 in the persistence of *Leishmania major* in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. *J Exp Med* **194** 1497-1506
- Belkaid Y, Piccirillo CA, Mendez S, Shevach EM and Sacks DL (2002) CD4+CD25+ regulatory T cells control *Leishmania major* persistence and immunity. *Nature* **420** 502-507
- Bermejo DA, Jackson SW, Gorosito-Serran M, Acosta-Rodriguez EV and Amezcua-Vesely MC (2013) *Trypanosoma cruzi* trans-sialidase initiates a program independent of the transcription factors RORgammat and Ahr that leads to IL-17 production by activated B cells. *Nat Immunol* **14** 514-522
- Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL and Kuchroo VK (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. *Nature* **441**: 235-238
- Bhowmick S and Ali N (2009) Identification of novel *Leishmania donovani* antigens that help define correlates of vaccine-mediated protection in visceral leishmaniasis. *PLoS One* **4** e5820.
- Bhowmick S, Mazumdar T and Ali N (2009) Vaccination route that induces transforming growth factor beta production fails to elicit protective immunity against *Leishmania donovani* infection. *Infect Immun* **77** 1514-1523
- Bhowmick S, Ravindran R and Ali N (2007) Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response. *Vaccine* **25** 6544-6556
- Bhowmick S, Ravindran R and Ali N (2008) gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with *Leishmania donovani*. *Infect Immun* **76** 1003-1015
- Biedermann T, Zimmermann S, Himmelrich H, Gumy A, Egeter O, Sakrauski, AK, Seegmuller I, Voigt H, Launois P, Levine AD, Wagner H, Heeg K, Louis JA and Rocken M (2001) IL-4 instructs TH1 responses and resistance to *Leishmania major* in susceptible BALB/c mice. *Nat Immunol* **2** 1054-1060
- Bihl F, Pecheur J, Breart B, Poupon G, Cazareth J, Julia V, Glaichenhaus N and Braud VM (2010) Primed antigen-specific CD4+ T cells are required for NK cell activation in vivo upon *Leishmania major* infection. *J Immunol* **185** 2174-2181
- Bilate AM and Lafaille JJ (2012) Induced CD4+Foxp3+ regulatory T cells in immune tolerance. *Annu Rev Immunol* **30** 733-758

- Boaventura VS, Santos CS, Cardoso CR, de Andrade J and Dos Santos WL (2010) Human mucosal leishmaniasis: neutrophils infiltrate areas of tissue damage that express high levels of Th17-related cytokines. *Eur J Immunol* **40** 2830-2836
- Bogdan C (2012) Natural killer cells in experimental and human leishmaniasis. *Front Cell Infect Microbiol* **2** 69
- Bourreau E, Prevot G, Pradinaud R and Launois P (2001) Unresponsiveness of specific T cells to IL-12 is associated with active cutaneous leishmaniasis owing to *Leishmania guyanensis*. *Scand J Immunol* **54** 335-339
- Bourreau E, Ronet C, Darcissac E, Lise MC, Sainte Marie D, Clity E, Tacchini-Cottier F, Couppie P and Launois P (2009) Intralesional regulatory T-cell suppressive function during human acute and chronic cutaneous leishmaniasis due to *Leishmania guyanensis*. *Infect Immun* **77** 1465-1474
- Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y and Zychlinsky A (2004) Neutrophil extracellular traps kill bacteria. *Science* **303** 1532-1535
- Bryceson AD (1970) Diffuse cutaneous leishmaniasis in Ethiopia. 3. Immunological studies. IV. Pathogenesis of diffuse cutaneous leishmaniasis. *Trans R Soc Trop Med Hyg* **64** 380-393
- Buxbaum LU (2013) *Leishmania mexicana* infection induces IgG to parasite surface glycoinositol phospholipids that can induce IL-10 in mice and humans. *PLoS Negl Trop Dis* **7** e2224
- Campanelli AP, Roselino AM, Cavassani KA, Pereira MS, Mortara RA, Belkaid Y, Barral-Netto M, Barral A and Silva JS (2006) CD4+CD25+ T cells in skin lesions of patients with cutaneous leishmaniasis exhibit phenotypic and functional characteristics of natural regulatory T cells. *J Infect Dis* **193** 1313-1322
- Castellano LR, Filho DC, Argiro L, Dessein H, Prata A, Dessein A and Rodrigues V (2009) Th1/Th2 immune responses are associated with active cutaneous leishmaniasis and clinical cure is associated with strong interferon-gamma production. *Hum Immunol* **70** 383-390
- Cezario GA, de Oliveira LR, Peresi E, Nicolette VC, Poletini J, de Lima CR, Gatto M and Calvi SA (2011) Analysis of the expression of toll-like receptors 2 and 4 and cytokine production during experimental *Leishmania chagasi* infection. *Mem Inst Oswaldo Cruz* **106** 573-583
- Chan CW, Crafton E, Fan HN, Flook J, Yoshimura K, Dubensky TW, Stins MF, Lanier LL, Pardoll DM and Housseau F (2006) Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. *Nat Med* **12** 207-213
- Chang CC, Ciubotariu R, Manavalan JS, Yuan J, Colovai AI, Colonna M, Cortesini R, Dalla-Favera R and Suciuc-Focan N (2002) Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. *Nat Immunol* **3** 237-243
- Chen J and Liu XS (2009) Development and function of IL-10 IFN-gamma-secreting CD4(+) T cells. *J Leukoc Biol* **86** 1305-1310
- Chen M, Su W, Lin X, Guo Z, Wang J, Zhang Q, Brand D, Ryffel B, Huang J, Liu Z, He X, Le AD and Zheng SG (2013) Adoptive transfer of human gingiva-derived mesenchymal stem cells ameliorates collagen-induced arthritis VIA suppressing Th1 and Th17 and enhancing regulatory T cell differentiation. *Arthritis Rheum*
- Chen Z, Tato CM, Muul L, Laurence A and O'Shea JJ (2007) Distinct regulation of interleukin-17 in human T helper lymphocytes. *Arthritis Rheum* **56** 2936-2946
- Choi CM and Lerner EA (2001) Leishmaniasis as an emerging infection. *J Invest Dermatol Symp Proc* **6** 175-182
- Collison LW, Chaturvedi V, Henderson AL, Giacomini PR, Guy C, Bankoti J, Finkelstein D, Forbes K, Workman CJ, Brown SA, Rehg JE, Jones ML, Ni HT, Artis D, Turk MJ and Vignali DA (2010) IL-35-mediated induction of a potent regulatory T cell population. *Nat Immunol* **11** 1093-1101
- Collison LW and Vignali DA (2008) Interleukin-35: odd one out or part of the family? *Immunol Rev* **226** 248-262
- Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y and Vignali DA (2007) The inhibitory cytokine IL-35 contributes to regulatory T-cell function. *Nature* **450** 566-569
- Colmenares M, Kar S, Goldsmith-Pestana K and McMahon-Pratt D (2002) Mechanisms of pathogenesis: differences amongst *Leishmania* species. *Trans R Soc Trop Med Hyg* **96** Suppl 1 S3-7
- Costa AS, Costa GC, de Aquino DM, de Mendonca VR, Barral A, Barral-Netto M and Caldas Ade J (2012) Cytokines and visceral leishmaniasis: A comparison of plasma cytokine profiles between the clinical forms of visceral leishmaniasis. *Mem Inst Oswaldo Cruz* **107** 735-739
- Cotterell SE, Engwerda CR and Kaye PM (1999) *Leishmania donovani* infection initiates T cell-independent chemokine responses, which are subsequently amplified in a T cell-dependent manner. *Eur J Immunol* **29** 203-214
- Courret N, Frehel C, Gouhier N, Pouchelet M, Prina E, Roux P and Antoine JC (2002) Biogenesis of *Leishmania*-harbouring parasitophorous vacuoles following phagocytosis of the metacyclic promastigote or amastigote stages of the parasites. *J Cell Sci* **115** 2303-2316

- Cruz A, Khader SA, Torrado E, Fraga A, Pearl JE, Pedrosa J, Cooper AM and Castro AG (2006) Cutting edge: IFN-gamma regulates the induction and expansion of IL-17-producing CD4 T cells during mycobacterial infection. *J Immunol* **177** 1416-1420
- de Assis Souza M, Brelaz de Castro MC, de Oliveira AP, de Almeida AF and de Almeida TM (2013) Cytokines and NO in American tegumentary leishmaniasis patients: Profiles in active disease, after therapy and in self-healed individuals. *Microb Pathog* **57** 27-32
- Dermine JF, Goyette G, Houde M, Turco SJ and Desjardins M (2005) *Leishmania donovani* lipophosphoglycan disrupts phagosome microdomains in J774 macrophages. *Cell Microbiol* **7** 1263-1270
- Deshmane SL, Kremlev S, Amini S and Sawaya BE (2009) Monocyte chemoattractant protein-1 (MCP-1): an overview. *J Interferon Cytokine Res* **29** 313-326
- Dhaliwal JS, Liew FY and Cox FE (1985) Specific suppressor T cells for delayed-type hypersensitivity in susceptible mice immunized against cutaneous leishmaniasis. *Infect Immun* **49** 417-423
- dos Santos MS, Vaz Cardoso LP, Nascimento GR, Lino Rde S, Jr Dorta ML, de Oliveira MA and Ribeiro-Dias F (2008) *Leishmania major*: recruitment of Gr-1+ cells into draining lymph nodes during infection is important for early IL-12 and IFN gamma production. *Exp Parasitol* **119** 403-410
- Dudeck A, Suender CA, Kostka SL, von Stebut E and Maurer M (2011) Mast cells promote Th1 and Th17 responses by modulating dendritic cell maturation and function. *Eur J Immunol* **41** 1883-1893
- Ebinuma H, Nakamoto N, Li Y, Price DA, Gostick E, Tobias J, Kwok WW and Chang KM (2008) Identification and *in vitro* expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection. *J Virol* **82** 5043-5053
- Farber JM (1997) Mig and IP-10: CXC chemokines that target lymphocytes. *J Leukoc Biol* **61** 246-257
- Filardy AA, Pires DR, Nunes MP, Takiya CM, Freire-de-Lima CG, Ribeiro-Gomes, FL and DosReis GA (2010) Proinflammatory clearance of apoptotic neutrophils induces an IL-12(low) IL-10(high) regulatory phenotype in macrophages. *J Immunol* **185** 2044-2050
- Fitzgerald DC, Zhang GX, El-Behi M, Fonseca-Kelly Z, Li H, Saris CJ, Gran B, Ciric B and Rostami A (2007) Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. *Nat Immunol* **8** 1372-1379
- Ghalib HW, Piuvezam MR, Skeiky YA, Siddig M, Hashim FA, el-Hassan AM, Russo DM and Reed SG (1993) Interleukin 10 production correlates with pathology in human *Leishmania donovani* infections. *J Clin Invest* **92** 324-329
- Ghosh K, Sharma G, Saha A, Kar S, Das PK and Ukil A (2013) Successful therapy of visceral leishmaniasis with curdlan involves T-helper 17 cytokines. *J Infect Dis* **207** 1016-1025
- Gidwani K, Rai M, Chakravarty J, Boelaert M and Sundar S (2009) Evaluation of leishmanin skin test in Indian visceral leishmaniasis. *Am J Trop Med Hyg* **80** 566-567
- Gonzalez-Lombana C, Gimblet C, Bacellar O, Oliveira WW, Passos S, Carvalho LP, Goldschmidt M, Carvalho EM and Scott P (2013) IL-17 Mediates Immunopathology in the Absence of IL-10 Following *Leishmania major* Infection. *PLoS Pathog* **9** e1003243
- Gregory DJ, Godbout M, Contreras I, Forget G and Olivier M (2008) A novel form of NF-kappa B is induced by *Leishmania* infection: involvement in macrophage gene expression. *Eur J Immunol* **38** 1071-1081
- Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE and Roncarolo MG (1997) A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. *Nature* **389** 737-742
- Guimaraes-Costa AB, Nascimento MT, Froment GS, Soares RP, Morgado FN, Conceicao-Silva F and Saraiva EM (2009) *Leishmania amazonensis* promastigotes induce and are killed by neutrophil extracellular traps. *Proc Natl Acad Sci U S A* **106** 6748-6753
- Gurunathan S, Stobie L, Prussin C, Sacks DL, Glaichenhaus N, Iwasaki A, Fowell DJ, Locksley RM, Chang JT, Wu CY and Seder RA (2000) Requirements for the maintenance of Th1 immunity *in vivo* following DNA vaccination: a potential immunoregulatory role for CD8+ T cells. *J Immunol* **165** 915-924
- Hailu A, van der Poll T, Berhe N and Kager PA (2004) Elevated plasma levels of interferon (IFN)-gamma, IFN-gamma inducing cytokines, and IFN-gamma inducible CXC chemokines in visceral leishmaniasis. *Am J Trop Med Hyg* **71** 561-567
- Hall AO, Beiting DP, Tato C, John B, Oldenhove G and Hunter CA *et al.* (2012) The cytokines interleukin 27 and interferon-gamma promote distinct Treg cell populations required to limit infection-induced pathology. *Immunity* **37** 511-523
- Harrington LE, Hatton RD, Mangan PR, Turner H and Murphy TL (2005) Interleukin 17-producing CD4+ effector T cells

- develop via a lineage distinct from the T helper type 1 and 2 lineages. *Nat Immunol* **6** 1123-1132
- Hayday A and Tigelaar R (2003) Immunoregulation in the tissues by gammadelta T cells. *Nat Rev Immunol* **3** 233-242
- Hedrich CM, Ramakrishnan A, Dabito D, Wang F, Ranatunga D and Bream JH (2010) Dynamic DNA methylation patterns across the mouse and human IL10 genes during CD4+ T cell activation; influence of IL-27. *Mol Immunol* **48** 73-81
- Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, Sugimoto N, Yamaguchi T, Nomura T, Ito H, Nakamura T, Sakaguchi N and Sakaguchi S (2007) Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. *J Exp Med* **204** 2803-2812
- Holland SM, DeLeo FR, Elloumi HZ, Hsu AP and Uzel G (2007) STAT3 mutations in the hyper-IgE syndrome. *N Engl J Med* **357** 1608-1619
- Howard JG, Hale C and Liew FY (1980) Immunological regulation of experimental cutaneous leishmaniasis. III. Nature and significance of specific suppression of cell-mediated immunity in mice highly susceptible to *Leishmania tropica*. *J Exp Med* **152** 594-607
- Howard JG, Hale C and Liew FY (1981) Immunological regulation of experimental cutaneous leishmaniasis. IV. Prophylactic effect of sublethal irradiation as a result of abrogation of suppressor T cell generation in mice genetically susceptible to *Leishmania tropica*. *J Exp Med* **153** 557-568
- Hunter CA and Kastelein R (2012) Interleukin-27: balancing protective and pathological immunity. *Immunity* **37** 960-969
- Hunter CA, Villarino A, Artis D and Scott P (2004) The role of IL-27 in the development of T-cell responses during parasitic infections. *Immunol Rev* **202** 106-114
- Hwang ES (2010) Transcriptional regulation of T helper 17 cell differentiation. *Yonsei Med J* **51** 484-491
- Ji J, Masterson J, Sun J and Soong L (2005) CD4+CD25+ regulatory T cells restrain pathogenic responses during *Leishmania amazonensis* infection. *J Immunol* **174** 7147-7153
- Jones LL and Vignali DA (2011) Molecular interactions within the IL-6/IL-12 cytokine/receptor superfamily. *Immunol Res* **51** 5-14
- Kamhawi S, Belkaid Y, Modi G, Rowton E and Sacks D (2000) Protection against cutaneous leishmaniasis resulting from bites of uninfected sand flies. *Science* **290** 1351-1354
- Kamiya S, Owaki T, Morishima N, Fukai F and Mizuguchi J, *et al.* (2004) An indispensable role for STAT1 in IL-27-induced T-bet expression but not proliferation of naive CD4+ T cells. *J Immunol* **173** 3871-3877
- Kastelein RA, Hunter CA and Cua DJ (2007) Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. *Annu Rev Immunol* **25** 221-242
- Katara GK, Ansari NA, Singh A, Ramesh V and Salotra P (2012) Evidence for involvement of Th17 type responses in post kala azar dermal leishmaniasis (PKDL). *PLoS Negl Trop Dis* **6** e1703
- Katara GK, Ansari NA, Verma S, Ramesh V and Salotra P (2011) Foxp3 and IL-10 expression correlates with parasite burden in lesional tissues of post kala azar dermal leishmaniasis (PKDL) patients. *PLoS Negl Trop Dis* **5** e1171
- Kautz-Neu K, Schwonberg K, Fischer MR, Schermann AI and von Stebut E (2012) Dendritic cells in *Leishmania major* infections: mechanisms of parasite uptake, cell activation and evidence for physiological relevance. *Med Microbiol Immunol* **201** 581-592
- Kaye PM, Svensson M, Ato M, Maroof A and Polley R (2004) The immunopathology of experimental visceral leishmaniasis. *Immunol Rev* **201** 239-253
- Kedzierski L, Curtis JM, Doherty PC, Handman E and Kedzierska K (2008) Decreased IL-10 and IL-13 production and increased CD44hi T cell recruitment contribute to *Leishmania major* immunity induced by non-persistent parasites. *Eur J Immunol* **38** 3090-3100
- Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J and Cooper MA (2007) IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. *Nat Immunol* **8** 369-377
- Kryczek I, Wu K, Zhao E, Wei S, Vatan L, Wang G and Zou W (2011) IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer. *J Immunol* **186** 4388-4395
- Kurkjian KM, Mahmutovic AJ, Kellar KL, Haque R, Bern C and Secor WE (2006) Multiplex analysis of circulating cytokines in the sera of patients with different clinical forms of visceral leishmaniasis. *Cytometry A* **69** 353-358
- Langrish CL, McKenzie BS, Wilson NJ, de Waal Malefyt R and Kastelein RA, *et al.* (2004) IL-12 and IL-23: master regulators of innate and adaptive immunity. *Immunol Rev* **202** 96-105

- Lanzavecchia A and Sallusto F (2005) Understanding the generation and function of memory T cell subsets. *Curr Opin Immunol* **17** 326-332
- Lapara NJ 3rd and Kelly BL (2010) Suppression of LPS-induced inflammatory responses in macrophages infected with *Leishmania*. *J Inflamm (Lond)* **7** 8
- Laskay T, Diefenbach A, Rollinghoff M and Solbach W (1995) Early parasite containment is decisive for resistance to *Leishmania major* infection. *Eur J Immunol* **25** 2220-2227
- Laskay T, van Zandbergen G and Solbach W (2003) Neutrophil granulocytes-Trojan horses for *Leishmania major* and other intracellular microbes? *Trends Microbiol* **11** 210-214
- Laufs H, Muller K, Fleischer J, Reiling N, Jahnke N, Jensenius JC, Solbach W and Laskay T (2002) Intracellular survival of *Leishmania major* in neutrophil granulocytes after uptake in the absence of heat-labile serum factors. *Infect Immun* **70** 826-835
- Li C, Toth I, Schulze Zur Wiesch J, Pereyra F, Rychert J, Rosenberg, ES, van Lunzen J, Lichterfeld M and Yu XG (2013) Functional Characterization of HLA-G(+) Regulatory T Cells in HIV-1 Infection. *PLoS Pathog* **9** e1003140
- Li L, Huang L, Vergis AL, Ye H, Bajwa A, Narayan V, Strieter RM, Rosin DL and Okusa MD (2010) IL-17 produced by neutrophils regulates IFN-gamma-mediated neutrophil migration in mouse kidney ischemia-reperfusion injury. *J Clin Invest* **120** 331-342
- Lin Y, Huang Y, Lu Z, Luo C, Shi Y, Zeng Q, Cao Y, Liu L, Wang X and Ji Q (2012) Decreased Plasma IL-35 Levels Are Related to the Left Ventricular Ejection Fraction in Coronary Artery Diseases. *PLoS One* **7** e52490
- Liu F, Tong F, He Y and Liu H (2011) Detectable expression of IL-35 in CD4+ T cells from peripheral blood of chronic hepatitis B patients. *Clin Immunol* **139** 1-5
- Liu H and Rohowsky-Kochan C (2008) Regulation of IL-17 in human CCR6+ effector memory T cells. *J Immunol* **180** 7948-7957
- Locksley RM, Heinzel FP, Fankhauser JE, Nelson CS and Sadick MD (1988) Cutaneous host defense in leishmaniasis: interaction of isolated dermal macrophages and epidermal Langerhans cells with the insect-stage promastigote. *Infect Immun* **56** 336-342
- Lund JM, Hsing L, Pham TT and Rudensky AY (2008) Coordination of early protective immunity to viral infection by regulatory T cells. *Science* **320** 1220-1224
- Malherbe L, Filippi C, Julia V, Foucras G, Moro M, Appel H, Wucherpfennig K, Guery JC and Glaichenhaus N (2000) Selective activation and expansion of high-affinity CD4+ T cells in resistant mice upon infection with *Leishmania major*. *Immunity* **13** 771-782
- Manel N, Unutmaz D and Littman DR (2008) The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgamma. *Nat Immunol* **9**: 641-649
- Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl, SM, Schoeb TR and Weaver CT (2006) Transforming growth factor-beta induces development of the T(H)17 lineage. *Nature* **441** 231-234
- Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M and Sallusto F (2004) Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. *Nat Immunol* **5** 1260-1265
- Matte C and Descoteaux A (2010) *Leishmania donovani* amastigotes impair gamma interferon-induced STAT1alpha nuclear translocation by blocking the interaction between STAT1alpha and importin-alpha5. *Infect Immun* **78** 3736-3743
- Maurya R, Kumar R, Prajapati VK, Manandhar KD, Sacks D, Sundar S and Nysten S (2010) Human visceral leishmaniasis is not associated with expansion or accumulation of Foxp3+ CD4 cells in blood or spleen. *Parasite Immunol* **32** 479-483
- Mazumdar T, Anam K and Ali N (2004) A mixed Th1/Th2 response elicited by a liposomal formulation of *Leishmania* vaccine instructs Th1 responses and resistance to *Leishmania donovani* in susceptible BALB/c mice. *Vaccine* **22** 1162-1171
- Mazumder S, Ganguly A and Ali N (2010) The effect of C-terminal domain deletion on the catalytic activity of *Leishmania donovani* surface proteinase GP63: Role of Ser446 in proteolysis. *Biochimie* **92** 1876-1885
- Mazumder S, Maji M and Ali N (2011a) Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection. *PLoS Negl Trop Dis* **5** e1429
- Mazumder S, Maji M, Das A and Ali N (2011b) Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against *Leishmania donovani* in BALB/c mice. *PLoS One* **6** e14644
- Modi WS and Yoshimura T (1999) Isolation of novel GRO genes and a phylogenetic analysis of the CXC chemokine subfamily in mammals. *Mol Biol Evol* **16** 180-193
- Mosser DM and Edelson PJ (1985) The mouse macrophage receptor for C3bi (CR3) is a major mechanism in the

- phagocytosis of *Leishmania* promastigotes. *J Immunol* **135** 2785-2789
- Muller K, van Zandbergen G, Hansen B, Laufs H, Jahnke N, Solbach W and Laskay T (2001) Chemokines, natural killer cells and granulocytes in the early course of *Leishmania* major infection in mice. *Med Microbiol Immunol* **190** 73-76
- Murray HW, Jungbluth A, Ritter E, Montelibano C and Marino MW (2000) Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment. *Infect Immun* **68** 6289-6293
- Murray HW, Lu CM, Brooks EB, Fichtl RE, DeVecchio JL and Heinzl FP (2003) Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis. *Infect Immun* **71** 6453-6462
- Murray HW, Lu CM, Mauze S, Freeman S, Moreira AL, Kaplan G and Coffman RL (2002) Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. *Infect Immun* **70** 6284-6293
- Murugaiyan G, Mittal A, Lopez-Diego R, Maier LM, Anderson DE and Weiner HL (2009) IL-27 is a key regulator of IL-10 and IL-17 production by human CD4+ T cells. *J Immunol* **183** 2435-2443
- Murugaiyan G and Saha B (2013) IL-27 in tumor immunity and immunotherapy. *Trends Mol Med*
- Muzio M, Bosisio D, Polentarutti N, D'Amico G, Stoppacciaro A, Mancinelli R, van't Veer C, Penton-Rol G, Ruco LP, Allavena P and Mantovani A (2000) Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. *J Immunol* **164** 5998-6004
- Natividad KD, Junankar SR, Mohd Redzwan N, Nair R, Wirasinha RC, King C, Brink R, Swarbrick A and Batten M (2013) Interleukin-27 Signaling Promotes Immunity against Endogenously Arising Murine Tumors. *PLoS One* **8** e57469
- Nawijn MC, Motta AC, Gras R, Shirinbak S, Maazi H and van Oosterhout AJ (2013) TLR-2 Activation Induces Regulatory T Cells and Long-Term Suppression of Asthma Manifestations in Mice. *PLoS One* **8** e55307
- Noble A, Giorgini A and Leggat JA (2006) Cytokine-induced IL-10-secreting CD8 T cells represent a phenotypically distinct suppressor T-cell lineage. *Blood* **107** 4475-4483
- Novoa R, Bacellar O, Nascimento M, Cardoso TM, Ramasawmy R, Oliveira WN, Schriefer A and Carvalho EM (2011) IL-17 and Regulatory Cytokines (IL-10 and IL-27) in *L. braziliensis* Infection. *Parasite Immunol* **33** 132-136
- Nylen S, Maurya R, Eidsmo L, Manandhar KD, Sundar S and Sacks D (2007) Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. *J Exp Med* **204** 805-817
- Nylen S and Sacks D (2007) Interleukin-10 and the pathogenesis of human visceral leishmaniasis. *Trends Immunol* **28** 378-384
- Okwor I, Liu D, Beverley SM and Uzonna JE (2009) Inoculation of killed *Leishmania* major into immune mice rapidly disrupts immunity to a secondary challenge via IL-10-mediated process. *Proc Natl Acad Sci USA* **106** 13951-13956
- Olson BM, Jankowska-Gan E, Becker JT, Vignali DA, Burlingham WJ and McNeel DG (2012) Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. *J Immunol* **189** 5590-5601
- Ota H, Takashima Y, Matsumoto Y, Hayashi Y and Matsumoto Y (2008) Pretreatment of macrophages with the combination of IFN-gamma and IL-12 induces resistance to *Leishmania major* at the early phase of infection. *J Vet Med Sci* **70** 589-593
- Owens BM, Beattie L, Moore JW, Brown N, Mann JL, Dalton JE, Maroof A and Kaye PM (2012) IL-10-producing Th1 cells and disease progression are regulated by distinct CD11c(+) cell populations during visceral leishmaniasis. *PLoS Pathog* **8** e1002827
- Pakpour N, Zaph C and Scott P (2008) The central memory CD4+ T cell population generated during *Leishmania* major infection requires IL-12 to produce IFN-gamma. *J Immunol* **180** 8299-8305
- Perona-Wright G, Kohlmeier JE, Bassity E, Freitas TC, Mohrs K, Cookenham T, Situ H, Pearce EJ, Woodland DL and Mohrs M (2012) Persistent loss of IL-27 responsiveness in CD8+ memory T cells abrogates IL-10 expression in a recall response. *Proc Natl Acad Sci U S A* **109** 18535-18540
- Peruhype-Magalhaes V, Martins-Filho OA, Prata A, Silva Lde A, Rabello A, Teixeira-Carvalho A, Figueiredo, RM, Guimaraes-Carvalho SF, Ferrari TC and Correa-Oliveira R (2005) Immune response in human visceral leishmaniasis: analysis of the correlation between innate immunity cytokine profile and disease outcome. *Scand J Immunol* **62** 487-495
- Peters NC, Egen JG, Secundino N, Debrabant A, Kimblin N, Kamhawi S, Lawyer P, Fay MP, Germain RN and Sacks D (2008) In vivo imaging reveals an essential role for

- neutrophils in leishmaniasis transmitted by sand flies. *Science* **321**: 970-974
- Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H and Kastelein RA (2002) IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. *Immunity* **16** 779-790
- Pitta MG, Romano A, Cabantous S, Henri S, Hammad A, Kouriba B, Argiro L, el Kheir M, Bucheton B, Mary C, El-Safi SH and Dessein A (2009) IL-17 and IL-22 are associated with protection against human kala azar caused by *Leishmania donovani*. *J Clin Invest* **119** 2379-2387
- Polley R, Sanos SL, Prickett S, Haque A and Kaye PM (2005) Chronic *Leishmania donovani* infection promotes bystander CD8+-T-cell expansion and heterologous immunity. *Infect Immun* **73** 7996-8001
- Qi H, Ji J, Wanassen N and Soong L (2004) Enhanced replication of *Leishmania amazonensis* amastigotes in gamma interferon-stimulated murine macrophages: implications for the pathogenesis of cutaneous leishmaniasis. *Infect Immun* **72** 988-995
- Qin S, Cobbold SP, Pope H, Elliott J, Kioussis D, Davies J and Waldmann H (1993) "Infectious" transplantation tolerance. *Science* **259** 974-977
- Racoosin EL and Beverley SM (1997) *Leishmania major*: promastigotes induce expression of a subset of chemokine genes in murine macrophages. *Exp Parasitol* **85** 283-295
- Rai AK, Thakur CP, Singh A, Seth T, Srivastava SK and Mitra DK (2012) Regulatory T cells suppress T cell activation at the pathologic site of human visceral leishmaniasis. *PLoS One* **7** e31551
- Ravichandran KS and Lorenz U (2007) Engulfment of apoptotic cells: signals for a good meal. *Nat Rev Immunol* **7** 964-974
- Ravindran R, Maji M and Ali N (2012) Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route. *Mol Pharm* **9** 59-70
- Reinhard K, Huber M, Lohoff M and Visekruna A (2012) The role of NF-kappaB activation during protection against *Leishmania* infection. *Int J Med Microbiol* **302** 230-235
- Reinhard K, Huber M, Wostl C, Hellhund A, Toboldt A, Abass E, Casper B, Joeris T, Herr C, Bals R, Steinhoff U, Lohoff M and Visekruna A (2011) c-Rel promotes type 1 and type 17 immune responses during *Leishmania major* infection. *Eur J Immunol* **41** 1388-1398
- Ritter U and Moll H (2000) Monocyte chemotactic protein-1 stimulates the killing of *Leishmania major* by human monocytes, acts synergistically with IFN-gamma and is antagonized by IL-4. *Eur J Immunol* **30** 3111-3120
- Rodrigues FM, Coelho Neto GT, Menezes JG, Gama ME and Goncalves EG (2013) Expression of Foxp3, TGF-beta and IL-10 in American cutaneous leishmaniasis lesions. *Arch Dermatol Res*
- Rodrigues OR, Marques C, Soares-Clemente M, Ferronha MH and Santos-Gomes GM (2009) Identification of regulatory T cells during experimental *Leishmania infantum* infection. *Immunobiology* **214** 101-111
- Rodriguez-Pinto D, Navas A, Blanco VM, Ramirez L, Garcerant D, Cruz A, Craft N and Saravia NG (2012) Regulatory T cells in the pathogenesis and healing of chronic human dermal leishmaniasis caused by *Leishmania (Viannia)* species. *PLoS Negl Trop Dis* **6** e1627
- Rodriguez-Sosa M, Monteforte GM and Satoskar AR (2001) Susceptibility to *Leishmania mexicana* infection is due to the inability to produce IL-12 rather than lack of IL-12 responsiveness. *Immunol Cell Biol* **79** 320-322
- Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K and Levings MK (2006) Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. *Immunol Rev* **212** 28-50
- Rosas LE, Satoskar AA, Roth KM, Keiser TL, Barbi J, Hunter C, de Sauvage FJ and Satoskar AR (2006) Interleukin-27R (WSX-1/T-cell cytokine receptor) gene-deficient mice display enhanced resistance to *leishmania donovani* infection but develop severe liver immunopathology. *Am J Pathol* **168** 158-169
- Rousseau D, Demartino S, Anjuere F, Ferrua B, Fragaki K, Le Fichoux Y and Kubar J (2001) Sustained parasite burden in the spleen of *Leishmania infantum*-infected BALB/c mice is accompanied by expression of MCP-1 transcripts and lack of protection against challenge. *Eur Cytokine Netw* **12** 340-347
- Roychoudhury J, Sinha R and Ali N (2011) Therapy with sodium stibogluconate in stearylamine-bearing liposomes confers cure against SSG-resistant *Leishmania donovani* in BALB/c mice. *PLoS One* **6** e17376
- Rutz S, Janke M, Kassner N, Hohnstein T, Krueger M and Scheffold A (2008) Notch regulates IL-10 production by T helper 1 cells. *Proc Natl Acad Sci U S A* **105** 3497-3502
- Ryba-Stanislawowska M, Skrzypkowska M, Mysliwiec M and Mysliwska J (2013) Loss of the balance between CD4(+)Foxp3(+) regulatory T cells and CD4(+)IL17A(+) Th17 cells in patients with type 1 diabetes. *Hum Immunol*

- Sacks D and Kamhawi S (2001) Molecular aspects of parasite-vector and vector-host interactions in leishmaniasis. *Annu Rev Microbiol* **55** 453-483
- Sacks DL, Lal SL, Shrivastava SN, Blackwell J and Neva FA (1987) An analysis of T cell responsiveness in Indian kala-azar. *J Immunol* **138** 908-913
- Saha S, Mondal S, Banerjee A, Ghose J, Bhowmick S and Ali N (2006) Immune responses in kala-azar. *Indian J Med Res* **123** 245-266
- Saha S, Mondal S, Ravindran R, Bhowmick S, Modak D and Ali N (2007) IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of *Leishmania donovani* infection in India. *J Immunol* **179** 5592-5603
- Sakaguchi S, Miyara M, Costantino CM and Hafler DA (2010) FOXP3+ regulatory T cells in the human immune system. *Nat Rev Immunol* **10** 490-500
- Sakaguchi S, Sakaguchi N, Asano M, Itoh M and Toda M (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. *J Immunol* **155** 1151-1164
- Santarasci V, Maggi L, Capone M, Frosali F, Querci V, De Palma R, Liotta F, Cosmi L, Maggi E, Romagnani S and Annunziato F (2009) TGF-beta indirectly favors the development of human Th17 cells by inhibiting Th1 cells. *Eur J Immunol* **39** 207-215
- Satoskar AR, Rodig S, Telford SR, 3rd, Satoskar AA, Ghosh SK, *et al.* (2000) IL-12 gene-deficient C57BL/6 mice are susceptible to *Leishmania donovani* but have diminished hepatic immunopathology. *Eur J Immunol* **30** 834-839
- Satoskar AR, Stamm LM, Zhang X, Satoskar AA, Okano M, Terhorst C, David JR and Wang B (1999) Mice lacking NK cells develop an efficient Th1 response and control cutaneous *Leishmania major* infection. *J Immunol* **162** 6747-6754
- Scott P (2003) Development and regulation of cell-mediated immunity in experimental leishmaniasis. *Immunol Res* **27** 489-498
- Sharma PK, Saha PK, Singh A, Sharma SK, Ghosh B and Mitra DK (2009) FoxP3+ regulatory T cells suppress effector T-cell function at pathologic site in miliary tuberculosis. *Am J Respir Crit Care Med* **179** 1061-1070
- Soong L, Henard CA and Melby PC (2012) Immunopathogenesis of non-healing American cutaneous leishmaniasis and progressive visceral leishmaniasis. *Semin Immunopathol* **34** 735-751
- Stager S, Alexander J, Kirby AC, Botto M, Rooijen NV, Smith DF, Brombacher F and Kaye PM (2003) Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses. *Nat Med* **9** 1287-1292
- Stager S, Maroof A, Zubairi S, Sanos SL, Kopf M and Kaye PM (2006) Distinct roles for IL-6 and IL-12p40 in mediating protection against *Leishmania donovani* and the expansion of IL-10+ CD4+ T cells. *Eur J Immunol* **36** 1764-1771
- Stanley AC and Engwerda CR (2007) Balancing immunity and pathology in visceral leishmaniasis. *Immunol Cell Biol* **85** 138-147
- Stumhofer JS, Laurence A, Wilson EH, Huang E, Tato CM, Hennighausen L, Ernst M and Hunter CA (2006) Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. *Nat Immunol* **7** 937-945
- Stumhofer JS, Silver JS, Laurence A, Porrett PM, Harris TH, Turka LA, Ernst M, Saris CJ, O'Shea JJ and Hunter CA (2007) Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. *Nat Immunol* **8** 1363-1371
- Takeda A, Hamano S, Yamanaka A, Hanada T, Ishibashi T, *et al.* (2003) Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. *J Immunol* **170** 4886-4890
- Tang Q and Bluestone JA (2008) The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. *Nat Immunol* **9** 239-244
- Tarbell KV, Petit L, Zuo X, Toy P and Luo X (2007) Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. *J Exp Med* **204** 191-201
- Tiwananthagorn S, Iwabuchi K, Ato M, Sakurai T, Kato H and Katakura K (2012) Involvement of CD4(+) Foxp3(+) regulatory T cells in persistence of *Leishmania donovani* in the liver of alymphoplastic aly/aly mice. *PLoS Negl Trop Dis* **6** e1798
- Tolouei S, Ghaedi K, Khamesipour A, Akbari M, Baghaei M, Hasheminia S, Narimani M and Hejazi S (2012) IL-23 and IL-27 Levels in Macrophages Collected from Peripheral Blood of Patients with Healing Vs Non-Healing Form of Cutaneous Leishmaniasis. *Iran J Parasitol* **7** 18-25
- Uzonon JE, Joyce KL and Scott P (2004) Low dose *Leishmania major* promotes a transient T helper cell type 2 response that is down-regulated by interferon gamma-producing CD8+ T cells. *J Exp Med* **199** 1559-1566

- van Zandbergen G, Hermann N, Laufs H, Solbach W and Laskay T (2002) *Leishmania* promastigotes release a granulocyte chemotactic factor and induce interleukin-8 release but inhibit gamma interferon-inducible protein 10 production by neutrophil granulocytes. *Infect Immun* **70** 4177-4184
- van Zandbergen G, Klinger M, Mueller A, Dannenberg S, Gebert A, Solbach W and Laskay T (2004) Cutting edge: neutrophil granulocyte serves as a vector for *Leishmania* entry into macrophages. *J Immunol* **173** 6521-6525
- Vester B, Muller K, Solbach W and Laskay T (1999) Early gene expression of NK cell-activating chemokines in mice resistant to *Leishmania major*. *Infect Immun* **67** 3155-3159
- Vignali DA, Collison LW and Workman CJ (2008) How regulatory T cells work. *Nat Rev Immunol* **8** 523-532
- Wang Z, Liu JQ, Liu Z, Shen R, Zhang G, Xu J, Basu S, Feng Y and Bai XF (2013) Tumor-Derived IL-35 Promotes Tumor Growth by Enhancing Myeloid Cell Accumulation and Angiogenesis. *J Immunol*
- Wang ZE, Reiner SL, Hatam F, Heinzl FP, Bouvier J, Turck CW and Locksley RM (1993) Targeted activation of CD8 cells and infection of beta 2-microglobulin-deficient mice fail to confirm a primary protective role for CD8 cells in experimental leishmaniasis. *J Immunol* **151** 2077-2086
- Wiethe C, Debus A, Mohrs M, Steinkasserer A, Lutz M and Gessner A (2008) Dendritic cell differentiation state and their interaction with NKT cells determine Th1/Th2 differentiation in the murine model of *Leishmania major* infection. *J Immunol* **180** 4371-4381
- Wing K and Sakaguchi S (2010) Regulatory T cells exert checks and balances on self tolerance and autoimmunity. *Nat Immunol* **11** 7-13
- Wojno ED and Hunter CA (2012) New directions in the basic and translational biology of interleukin-27. *Trends Immunol* **33** 91-97
- Workman CJ, Szymczak-Workman AL, Collison LW, Pillai MR and Vignali DA (2009) The development and function of regulatory T cells. *Cell Mol Life Sci* **66** 2603-2622
- Wu H, Li P, Shao N, Ma J, Ji M, Sun X, Ma D and Ji C (2012) Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF-beta in acute myeloid leukemia. *Oncol Lett* **3** 1119-1123
- Wu W, Huang L and Mendez S (2010) A live *Leishmania major* vaccine containing CpG motifs induces the de novo generation of Th17 cells in C57BL/6 mice. *Eur J Immunol* **40** 2517-2527
- Yoshimoto T, Yoshimoto T, Yasuda K, Mizuguchi J and Nakanishi K (2007) IL-27 suppresses Th2 cell development and Th2 cytokines production from polarized Th2 cells: a novel therapeutic way for Th2-mediated allergic inflammation. *J Immunol* **179** 4415-4423
- Zahn S, Wirtz S, Birkenbach M, Blumberg RS, Neurath MF, et al. (2005) Impaired Th1 responses in mice deficient in Epstein-Barr virus-induced gene 3 and challenged with physiological doses of *Leishmania major*. *Eur J Immunol* **35** 1106-1112
- Zaph C and Scott P (2003) Interleukin-12 regulates chemokine gene expression during the early immune response to *Leishmania major*. *Infect Immun* **71** 1587-1589
- Zer R, Yaroslavski I, Rosen L and Warburg A (2001) Effect of sand fly saliva on *Leishmania* uptake by murine macrophages. *Int J Parasitol* **31** 810-814
- Zhang S, Liang R, Luo W, Liu C and Wu X (2013) High susceptibility to liver injury in IL-27 p28 conditional knockout mice involves intrinsic interferon-gamma dysregulation of CD4(+) T cells. *Hepatology*
- Zhang ZX, Yang L, Young KJ, Du Temple B and Zhang L (2000) Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. *Nat Med* **6** 782-789
- Zhao L, Qiu de K and Ma X (2010) Th17 cells: the emerging reciprocal partner of regulatory T cells in the liver. *J Dig Dis* **11** 126-133
- Zhou L, Lopes JE, Chong MM, Ivanov, II, Min R, Shen Y, Du J, Rubtsov YP, Rudensky AY, Ziegler SF and Littman DR (2008) TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgamma function. *Nature* **453** 236-240.

